Advanced search
Publication Cover
Journal of Medical Economics Volume 18, 2015 - Issue 5
Submit an article Journal homepage
1,865
Views
7
CrossRef citations to date
0
Altmetric
Original article

Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service

Jameel NazirAstellas Pharma Europe Ltd, Chertsey, UKCorrespondence[email protected]
,
John PosnettHeron Commercialization, PAREXEL, London, UK
,
Anna WalkerHeron Commercialization, PAREXEL, London, UK
,
Isaac A. OdeyemiAstellas Pharma Europe Ltd, Chertsey, UK
,
Zalmai HakimiAstellas Pharma Global Development, Leiden, The Netherlands
&
Andrew GarnhamAstellas Pharma Europe Ltd, Chertsey, UK
Pages 390-397 | Accepted 02 Dec 2014, Published online: 19 Dec 2014

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Miriam O’Kane, Dudley Robinson, Linda Cardozo, Adrian Wagg & Paul Abrams. (2022) Mirabegron in the Management of Overactive Bladder Syndrome. International Journal of Women's Health 14, pages 1337-1350.
Read now
Robert Freeman, Steve Foley, José Rosa Arias, Eduardo Vicente, Robert Grill, Zuzana Kachlirova, Anny Stari, Moses Huang & Nurul Choudhury. (2018) Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Current Medical Research and Opinion 34:5, pages 785-793.
Read now
Zalmai Hakimi, Jameel Nazir, Charles McCrea, Malin Berling, Francis Fatoye, Barbara Ramos & Adrian Wagg. (2017) Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. Journal of Medical Economics 20:6, pages 614-622.
Read now

Articles from other publishers (4)

Sonya J. Snedecor. (2018) Review of Economic Value Drivers of the Treatment of Overactive Bladder. PharmacoEconomics 36:9, pages 1083-1092.
Crossref
Jameel Nazir, Malin Berling, Charles McCrea, Francis Fatoye, Sally Bowditch, Zalmai Hakimi & Adrian Wagg. (2017) Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK. PharmacoEconomics - Open 1:1, pages 25-36.
Crossref
Kimberly Tay & Aqsa Khan. (2017) Patient Satisfaction on Overactive Bladder Treatment. Current Bladder Dysfunction Reports 12:1, pages 58-65.
Crossref
Ilias Giarenis, Dudley Robinson & Linda Cardozo. (2015) Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects. Drugs 75:15, pages 1707-1713.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.